Pictet & Cie (Europe) Sa Crispr Therapeutics Ag Transaction History

Pictet & Cie (Europe) Sa

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	SELL	$43.23 - $73.83 $195,356 - $333,637	-4,519 Closed	0 $0
Q1 2022 May 04, 2022	BUY	$53.19 - $79.24 $23,563 - $35,103	443 Added 10.87%	4,519 $284,000
Q4 2021 Feb 02, 2022	BUY	$70.09 - $111.29 $37,287 - $59,206	532 Added 15.01%	4,076 $309,000
Q3 2021 Nov 10, 2021	SELL	$110.2 - $156.64 $36,696 - $52,161	-333 Reduced 8.59%	3,544 $397,000
Q2 2021 Aug 11, 2021	BUY	$100.84 - $161.89 $390,956 - $627,647	3,877 New	3,877 $628,000

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.18B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Pictet & Cie (Europe) Sa, based on Form 13F filings with the SEC.

Stay updated on Pictet & Cie (Europe) Sa with notifications on news.